Comparative Pharmacology
Head-to-head clinical analysis: FINGOLIMOD HYDROCHLORIDE versus MAYZENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINGOLIMOD HYDROCHLORIDE versus MAYZENT.
FINGOLIMOD HYDROCHLORIDE vs MAYZENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.
Sphingosine 1-phosphate receptor modulator; binds with high affinity to S1P receptors 1 and 5 on lymphocytes, blocking egress from lymph nodes, reducing circulating lymphocytes.
0.5 mg orally once daily
0.25 mg orally once daily initially, titrated over several weeks to a maintenance dose of 2 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 6–9 days; due to extensive tissue distribution, steady-state is reached within 1–2 months of daily dosing.
Terminal elimination half-life is approximately 8–10 days due to slow dissociation from sphingosine 1-phosphate receptors; steady-state reached in 3–4 weeks.
Primarily hepatic metabolism (CYP4F2) with subsequent biliary/fecal elimination (81% of total clearance); renal excretion accounts for <2.5% of unchanged drug.
Primarily fecal (≈76% as metabolites) and renal (≈24% as metabolites and minor unchanged drug).
Category C
Category C
Sphingosine 1-Phosphate Receptor Modulator
Sphingosine 1-Phosphate Receptor Modulator